Abstract:In this study, we introduced a NADPH derivative named as Nanoshutter (NS). NS was designed to inhibit the catalytic activity of NOS, i.e. synthesis of NO, by occupying the NADPH site in the reductase domain of NOS. In mammals, NO participates in extensive physiological/pathological processes in the cardiovascular, nervous and immune systems. The pathway of mammal NO synthesis is the oxidation of L-arginine catalyzed by NOS, which occurs in its oxygenase domain. The catalysis requires three co-substrates (L-arginine, NADPH, and O2) and five cofactors groups (FAD, FMN, calmodulin, BH4 and heme). Guided by molecular modeling, the structure of NS contains two conjugated subunits: (i) the nucleotide recognition motif of NADPH was retained in NS, allowing a proper targeting to the NADPH binding site of NOS- (ii) the nicotinamide moiety of NADPH is replaced by a stilbene moiety linked with a terminal electron acceptor group, preventing electron flow from the reductase to the oxygenase domain of NOS. Furthermore, this moiety is characterized by a large two-photon absorption cross-section (130 at 840 nm). NS1, the first compound of the NS family, contains a NO2 terminal group as an electron acceptor group. NS1 displayed distinct fluorescence properties in its free and NOS-bound states. The Kd value (around 4.2 µM) was estimated in titration experiments performed under one- or two-photon excitation conditions, suggesting an effective binding of NS1 to NOS with a good affinity. Surprisingly, in terms of fluorescence quantum yield, NS1 displayed a good selectivity to the NOS isoforms over other proteins which contain or not a NADPH binding site. Furthermore, NS1 was shown to competitively inhibit nNOS in a dose-dependent manner. In fluorescence imaging experiments with endothelial cells (HUVEC), NS1 displayed a rapid and efficient internalization, with highlighted fluorescence signal at the perinucleus region and sporadic signal at the plasma membrane. This observation was in accordance with the colocalization imaging between NS1 and eNOS as shown by immunostaining, showing that NS1 actually targets eNOS in endothelial cells. The expected NO-dependent vasoconstriction in isolated mouse aortic rings was only evidenced in the presence of catalase, which converts H2O2 into H2O and O2. By contrast, in the absence of catalase, a contradictory vasorelaxation was observed. This result indicates that NS1 may target more than NOS in endothelium system, which is (are) likely related to Reactive Oxygen Species (ROS) production. Accordingly, NS1 led to a biphasic response of ROS production in HUVEC cells: An increasing phase occurred at low NS1 concentration (below 2 µM) and followed by a decreasing phase (ROS inhibition) at higher NS1 concentrations. Furthermore, NS1 was shown to inhibit O2- production in mouse macrophages and H2O2 and O2- production in uncoupled nNOS in vitro. Altogether, the possible but not exclusive explanations for current data are: in addition to its inhibition effect on NO production, NS1 probably also inhibits the ROS production either produced by NADPH Oxidase or by electron leakage from uncoupled NOS, or a combination of both. The origin of the increasing phase remains more elusive but could correspond to the targeting of glucose-6-phosphate-dehydrogenase (G6PD). Additionally, NS1 displayed anti-angiogenesis effect on endothelial cells and prevented proliferation of melanoma. In conclusion, NS1 fulfilled the goal as a new NOS inhibitor targeting the reductase domain and displayed a unique two-photon property in vitro and in vivo, these features may provide a promising future for non-invasive real-time imaging, and to potential clinical applications in the NO-dependent diseases.

Étude D'un Nouveau Composé À Propriété D'absorption Multiphotonique Dérivé Du NADPH Ciblant La NO-synthase

Gold Nanorod-Based Nanoplatform Catalyzes Constant NO Generation and Protects from Cardiovascular Injury

Single-Component Photo-Responsive Template for the Controlled Release of NO and H2S2

Multimodality Imaging of Nitric Oxide and Nitric Oxide Synthases

Selective and sensitive fluorescence imaging reveals microenvironment-dependent behavior of NO modulators in the endothelial system

Effect of NADPH oxidase inhibitors in an experimental retinal model of excitotoxicity

Nitric Oxide Activatable Photosensitizer Accompanying Extremely Elevated Two-Photon Absorption for Efficient Fluorescence Imaging and Photodynamic Therapy.

Inhibition of NOX1/4 with GKT137831: a potential novel treatment to attenuate neuroglial cell inflammation in the retina

Nitric oxide as an all-rounder for enhanced photodynamic therapy: Hypoxia relief, glutathione depletion and reactive nitrogen species generation

Local arterial nanoparticle delivery of siRNA for NOX2 knockdown to prevent restenosis in an atherosclerotic rat model

Tracing nitroxyl in vivo with a high fluorescence quantum yield and large Stokes shift near-infrared fluorescent probe

An activatable near-infrared fluorescent probe for tracking nitroxyl in vitro and in vivo

X-Ray Structure and enzymatic study of a Bacterial NADPH oxidase highlight the activation mechanism of eukaryotic NOX

An Activatable Fluorescent Probe for Imaging Endogenous Nitric Oxide Via the Enos Enzymatic Pathway

Biomimetic Activation of N-Nitrosamides with Red Light-Triggered Nitric Oxide Release via Mediated Electron Transfer

Deconvoluting Nitric Oxide-Protein Interactions with Spatially Resolved Multiplex Imaging

Supramolecular red-light-photosensitized nitric oxide release with fluorescence self-reporting within biocompatible nanocarriers

Metal-based optical probes for live cell imaging of nitroxyl (HNO)

Visualizing Peroxynitrite Fluxes in Endothelial Cells Reveals the Dynamic Progression of Brain Vascular Injury.

Effects of Pharmacological Inhibitors of NADPH Oxidase on Myogenic Contractility and Evoked Vasoactive Responses in Rat Resistance Arteries